KPTI vs KRRO

Karyopharm Therapeutics Inc. vs Korro Bio, Inc. — Valuation Comparison 2026

KPTI

Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
Quality
5.1
out of 10
Value Trap
30
LOW
Price
$9.10
Last close
Models
7/13
Active
VS

KRRO

Pharmaceutical Preparations
Korro Bio, Inc.
Quality
5.1
out of 10
Value Trap
28
LOW
Price
$13.41
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType KPTI Fair ValueKPTI Upside KRRO Fair ValueKRRO Upside
Bayesian DCF Intrinsic $3.13 -65.6% $3.85 -71.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $9.46 -29.4%
PWERM Option-Based $23.88 +162.4% $11.76 -12.3%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KPTI vs KRRO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KPTI vs KRRO — Which Stock Is More Undervalued?

KRRO scores higher with a 5.1/10 quality rating vs KPTI's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Karyopharm Therapeutics Inc. (KPTI) and Korro Bio, Inc. (KRRO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KPTI currently trades at $9.10 with a QOC of 5.1/10, while KRRO trades at $13.41 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).